Litcius/Paper detail

Juvenile dermatomyositis. Where are we now?

Liza McCann, Polly Livermore, Meredyth Wilkinson, Lucy R. Wedderburn

2022Clinical and Experimental Rheumatology72 citationsDOIOpen Access PDF

Abstract

Juvenile onset idiopathic inflammatory myopathy (IIM) has many similarities and distinct differences from adult-onset disease. This review will focus on recent developments in understanding and treatment of juvenile dermatomyositis (JDM), the most common disease sub-type of IIM in childhood. JDM is a systemic immune mediated vasculopathy, increasingly recognised as a group of distinct phenotypes with variable presentation and outlook. This overview will describe long-term outlook and disease course including health-related quality of life and emerging treatments.

Topics & Concepts

Juvenile dermatomyositisMedicineDermatomyositisDiseaseJuvenileMyopathyQuality of life (healthcare)Presentation (obstetrics)ImmunologyDermatologyPathologySurgeryNursingGeneticsBiologyInflammatory Myopathies and DermatomyositisCeliac Disease Research and ManagementAutoimmune Bullous Skin Diseases
Juvenile dermatomyositis. Where are we now? | Litcius